Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains and purpose-bred rats and mice for use by researchers. It also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets and chemical compounds through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. It also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company was founded in 1947 and is based in Wilmington, Massachusetts.
IPO Year: 2000
Exchange: NYSE
Website: criver.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
8/8/2024 | $239.00 → $191.00 | Outperform → Neutral | Robert W. Baird |
8/8/2024 | $270.00 → $205.00 | Overweight → Neutral | JP Morgan |
6/28/2024 | Buy → Hold | Argus | |
6/7/2024 | $235.00 | Neutral | Mizuho |
6/6/2024 | $290.00 | Buy | Goldman |
2/15/2024 | Buy → Neutral | Guggenheim | |
9/13/2023 | $212.00 | Market Perform | TD Cowen |
7/10/2023 | $260.00 → $225.00 | Buy → Neutral | Citigroup |
2/23/2023 | $255.00 | Neutral → Buy | Guggenheim |
1/12/2023 | Buy → Hold | Jefferies |
4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
4 - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Issuer)
Collaboration stands to advance novel therapeutic applications across multiple neurologic conditions Charles River Laboratories International, Inc. (NYSE:CRL) and Insightec, a global healthcare company dedicated to using focused ultrasound to transform patient care, today announced the launch of a five-year strategic collaboration to provide Charles River's clients access to a comprehensive global service and technology platform for the application of focused ultrasound (FUS) for drug discovery and preclinical development of therapeutics in neuroscience. Insightec's novel low-frequency ultrasound platform non-invasively disrupts the blood-brain barrier, enabling drugs to be delivered to t
Charles River Laboratories International, Inc. (NYSE:CRL) announced today that it will present at two upcoming investor conferences, including: Morgan Stanley 22nd Annual Global Healthcare Conference on Thursday, September 5th, at 9:15 a.m. EDT; and Baird 2024 Global Healthcare Conference on Tuesday, September 10th, at 10:15 a.m. EDT. Management will present an overview of Charles River's strategic focus, business developments, and recent trends. A live webcast of each presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com. A webcast replay will be accessible through the same website after
– Second-Quarter Revenue of $1.03 Billion – – Second-Quarter GAAP Earnings per Share of $1.74 and Non-GAAP Earnings per Share of $2.80 – – Board Approves New Stock Repurchase Authorization of $1.0 Billion – – Revises 2024 Guidance – Charles River Laboratories International, Inc. (NYSE:CRL) today reported its results for the second quarter of 2024. For the quarter, revenue was $1.03 billion, a decrease of 3.2% from $1.06 billion in the second quarter of 2023. The impact of foreign currency translation reduced reported revenue by 0.3%, a divestiture reduced reported revenue by 0.2%, and an acquisition contributed 0.5% to consolidated second-quarter revenue. Excluding the effect of t
Clinical trials for AAV9 gene therapy bolstered with plasmid and viral vector CDMO expertise Charles River Laboratories International, Inc. (NYSE:CRL) announced today a collaboration with the FOXG1 Research Foundation (FRF) highlighting the patient advocacy group's model to independently drive drug development through the clinical phase. The parent-led global organization driving the research to cure FOXG1 syndrome and related neurological disorders will collaborate with Charles River in a comprehensive gene therapy contract development and manufacturing organization (CDMO) agreement. "Charles River is proud to work with the FOXG1 Research Foundation to advance its gene-therapy through
Agreement establishes Charles River as the preferred partner for Autobahn Labs, leveraging drug discovery and development capabilities to accelerate the translation of academic discoveries into novel therapeutics Under the agreement, Charles River will make an equity investment in Autobahn Labs Justin Bryans, Chief Scientific Officer, Discovery at Charles River, named to Autobahn's Board of Directors Charles River Laboratories International, Inc. (NYSE:CRL) and Autobahn Labs, a Samsara BioCapital-backed virtual accelerator for academic biotech, today announced a collaborative relationship that establishes Charles River as the preferred research partner to support Autobahn's grow
Charles River Laboratories International, Inc. (NYSE:CRL) will release second-quarter 2024 financial results on Wednesday, August 7th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, August 7th, at 9:00 a.m. ET. Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at ir.criver.com. A replay will be accessible through the same website. About Charles River Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe acce
Critical starting material manufacture for therapeutic targeting high unmet need ophthalmology indication Charles River Laboratories International, Inc. (NYSE:CRL) and AAVantgarde today announced a contract development and manufacturing organization (CDMO) agreement to produce Good Manufacturing Practice- (GMP) plasmid DNA. AAVantgarde, a clinical-stage biotechnology company with two proprietary adeno-associated viral (AAV) vector platforms for large gene delivery and developing products to treat inherited retinal diseases, will leverage Charles River's expertise in manufacturing GMP plasmid DNA. AAVantgarde has two proprietary AAV-based large gene delivery platforms, both of which aim
Lentiviral vector CDMO collaboration to support advanced cell therapies for hematological cancers Charles River Laboratories International, Inc. (NYSE:CRL) and the Gates Institute at the University of Colorado Anschutz Medical Campus today announced a lentiviral vector contract development and manufacturing organization (CDMO) agreement. Gates Institute will leverage Charles River's premier cell and gene therapy CDMO expertise to develop Good Manufacturing Practice (GMP)-grade lentiviral vectors (LVVs) for use in novel chimeric antigen receptor (CAR) T-cell therapies for hematological cancers. The Gates Institute mission at the University of Colorado Anschutz Medical Campus is to develo
Leveraging CGT CDMO expertise to support T-cell immunotherapy clinical trial Charles River Laboratories International, Inc. (NYSE:CRL) and Captain T Cell, a spinoff from the renowned Max Delbrück Center Berlin, Germany, today announced a plasmid DNA and retrovirus vector production program agreement. As part of Charles River's Cell and Gene Therapy (CGT) Accelerator Program (CAP), Captain T Cell will have access to established plasmid and viral vector contract development and manufacturing organization (CDMO) capabilities and advisory services ahead of Captain T Cell's plan to manufacture a TCR-T cell therapy for solid tumor patients for a Phase I clinical trial. An Award-winning Approa
Project will utilize an integrated approach to develop an in vitro alternative to inhalation toxicology studies Charles River Laboratories International, Inc. (NYSE:CRL) today announced a multidisciplinary program, funded through a $1.3 million grant from the Foundation for Chemistry Research & Initiatives (FCRI), in coordination with the American Chemistry Council's Long-Range Research Initiative (ACC LRI), to develop a New Approach Methodology (NAM) inhalation toxicology test to reduce reliance on traditional animal research methods. The program is a collaboration between Charles River's Edinburgh, Scotland team, along with MatTek Corporation (in vitro EpiAirway™ model and expertise), d
Agreement establishes Charles River as the preferred partner for Autobahn Labs, leveraging drug discovery and development capabilities to accelerate the translation of academic discoveries into novel therapeuticsUnder the agreement, Charles River will make an equity investment in Autobahn LabsJustin Bryans, Chief Scientific Officer, Discovery at Charles River, named to Autobahn's Board of Directors
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Goldman Sachs raised the price target for Tesla, Inc. (NASDAQ:TSLA) from $175 to $248. Goldman Sachs analyst Mark Delaney maintained a Neutral rating. Tesla shares rose 3.7% to close at $262.33 on Tuesday. See how other analysts view this stock. Keybanc lifted the price target for Netflix, Inc. (NASDAQ:NFLX) from $707 to $735. Keybanc analyst Justin Patterson maintained an Overweight rating. Netflix shares closed at $685.74 on Tuesday. See how other analysts view this stock. B of A Securities cu
Baird analyst Eric Coldwell maintains Charles River (NYSE:CRL) with a Outperform and lowers the price target from $271 to $239.
Critical starting material manufacture for therapeutic targeting high unmet need ophthalmology indicationCharles River Laboratories International, Inc. (NYSE:CRL) and AAVantgarde today announced a contract development and manufacturing organization (CDMO) agreement to produce Good Manufacturing Practice- (GMP) plasmid DNA. AAVantgarde, a clinical-stage biotechnology company with two proprietary adeno-associated viral (AAV) vector platforms for large gene delivery and developing products to treat inherited retinal diseases, will leverage Charles River's expertise in manufacturing GMP plasmid DNA.AAVantgarde has two proprietary AAV-based large gene delivery platforms, both of which aim to enab
Barclays analyst Luke Sergott initiates coverage on Charles River (NYSE:CRL) with a Equal-Weight rating and announces Price Target of $230.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. JP Morgan analyst Matthew Boss downgraded NIKE, Inc. (NYSE:NKE) from Overweight to Neutral, while cutting the price target from $116 to $83. Nike shares gained 0.1% to close at $94.19 on Thursday. See how other analysts view this stock. Argus Research analyst David Toung downgraded the rating for Charles River Laboratories International, Inc. (NYSE:CRL) from Buy to Hold. Charles River shares gained 0.3% to close at $207.35 on Thursday. See how other analysts view this stock. Stifel
During the last three months, 4 analysts shared their evaluations of Charles River (NYSE:CRL), revealing diverse outlooks from bullish to bearish. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 1 2 0 0 Last 30D 0 0 0 0 0 1M Ago 1 0 1 0 0 2M Ago 0 1 1 0 0 3M Ago 0 0 0 0 0 Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $255.75, along with a high estimate of $290.00 and a low estimate of $228.00. This current average has
Argus Research analyst David Toung downgrades Charles River (NYSE:CRL) from Buy to Hold.
Lentiviral vector CDMO collaboration to support advanced cell therapies for hematological cancersCharles River Laboratories International, Inc. (NYSE:CRL) and the Gates Institute at the University of Colorado Anschutz Medical Campus today announced a lentiviral vector contract development and manufacturing organization (CDMO) agreement. Gates Institute will leverage Charles River's premier cell and gene therapy CDMO expertise to develop Good Manufacturing Practice (GMP)-grade lentiviral vectors (LVVs) for use in novel chimeric antigen receptor (CAR) T-cell therapies for hematological cancers.
– Second-Quarter Revenue of $1.03 Billion – – Second-Quarter GAAP Earnings per Share of $1.74 and Non-GAAP Earnings per Share of $2.80 – – Board Approves New Stock Repurchase Authorization of $1.0 Billion – – Revises 2024 Guidance – Charles River Laboratories International, Inc. (NYSE:CRL) today reported its results for the second quarter of 2024. For the quarter, revenue was $1.03 billion, a decrease of 3.2% from $1.06 billion in the second quarter of 2023. The impact of foreign currency translation reduced reported revenue by 0.3%, a divestiture reduced reported revenue by 0.2%, and an acquisition contributed 0.5% to consolidated second-quarter revenue. Excluding the effect of t
Charles River Laboratories International, Inc. (NYSE:CRL) will release second-quarter 2024 financial results on Wednesday, August 7th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, August 7th, at 9:00 a.m. ET. Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at ir.criver.com. A replay will be accessible through the same website. About Charles River Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe acce
– First-Quarter Revenue of $1.01 Billion – – First-Quarter GAAP Earnings per Share of $1.30 and Non-GAAP Earnings per Share of $2.27 – – Updates 2024 Guidance – Charles River Laboratories International, Inc. (NYSE:CRL) today reported its results for the first quarter of 2024. For the quarter, revenue was $1.01 billion, a decrease of 1.7% from $1.03 billion in the first quarter of 2023. The impact of foreign currency translation benefited reported revenue by 0.3%, and acquisitions contributed 1.5% to consolidated first-quarter revenue. A small divestiture of a Safety Assessment site reduced reported revenue by 0.2%. Excluding the effect of these items, organic revenue decreased 3.3%.
Charles River Laboratories International, Inc. (NYSE:CRL) will release first-quarter 2024 financial results on Thursday, May 9th, before the market opens. A conference call has been scheduled to discuss this information on Thursday, May 9th, at 8:30 a.m. ET. Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at ir.criver.com. A replay will be accessible through the same website. About Charles River Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate thei
– Fourth-Quarter Revenue of $1.01 Billion and Full-Year Revenue of $4.13 Billion – – Fourth-Quarter GAAP Earnings per Share of $3.62 and Non-GAAP Earnings per Share of $2.46 – – Full-Year GAAP Earnings per Share of $9.22 and Non-GAAP Earnings per Share of $10.67 – – Provides 2024 Guidance – Charles River Laboratories International, Inc. (NYSE:CRL) today reported its results for the fourth-quarter and full-year 2023 and provided guidance for 2024. For the quarter, revenue was $1.01 billion, a decrease of 7.9% from $1.10 billion in the fourth quarter of 2022. The impact of foreign currency translation benefited reported revenue by 1.2%, and acquisitions contributed 0.7% to consolida
Charles River Laboratories International, Inc. (NYSE:CRL) will release fourth-quarter and full-year 2023 financial results and provide 2024 guidance on Wednesday, February 14th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, February 14th, at 8:30 a.m. ET. Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at ir.criver.com. A replay will be accessible through the same website. About Charles River Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leadi
Charles River Laboratories International, Inc. (NYSE:CRL) will release third-quarter 2023 financial results on Wednesday, November 8th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, November 8th, at 8:30 a.m. ET. Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at ir.criver.com. A replay will be accessible through the same website. About Charles River Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe a
Charles River Laboratories International, Inc. (NYSE:CRL) will release second-quarter 2023 financial results on Wednesday, August 9th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, August 9th, at 8:30 a.m. ET. Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at ir.criver.com. A replay will be accessible through the same website. About Charles River Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe acce
Charles River Laboratories International, Inc. (NYSE:CRL) will release first-quarter 2023 financial results on Thursday, May 11th, before the market opens. A conference call has been scheduled to discuss this information on Thursday, May 11th, at 8:30 a.m. ET. Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at ir.criver.com. A replay will be accessible through the same website. About Charles River Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate
Charles River Laboratories International, Inc. (NYSE:CRL) will release fourth-quarter and full-year 2022 financial results and provide 2023 guidance on Wednesday, February 22nd, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, February 22nd, at 8:30 a.m. ET. Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at ir.criver.com. A replay will be accessible through the same website. About Charles River Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading
Robert W. Baird downgraded Charles River from Outperform to Neutral and set a new price target of $191.00 from $239.00 previously
JP Morgan downgraded Charles River from Overweight to Neutral and set a new price target of $205.00 from $270.00 previously
Argus downgraded Charles River from Buy to Hold
Mizuho initiated coverage of Charles River with a rating of Neutral and set a new price target of $235.00
Goldman initiated coverage of Charles River with a rating of Buy and set a new price target of $290.00
Guggenheim downgraded Charles River from Buy to Neutral
TD Cowen initiated coverage of Charles River with a rating of Market Perform and set a new price target of $212.00
Citigroup downgraded Charles River from Buy to Neutral and set a new price target of $225.00 from $260.00 previously
Guggenheim upgraded Charles River from Neutral to Buy and set a new price target of $255.00
Jefferies downgraded Charles River from Buy to Hold
10-Q - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Filer)
8-K - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Filer)
SD - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Filer)
8-K - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Filer)
S-3ASR - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Filer)
10-Q - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Filer)
8-K - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Filer)
DEFA14A - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Filer)
ARS - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Filer)
DEF 14A - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Filer)
Agreement establishes Charles River as the preferred partner for Autobahn Labs, leveraging drug discovery and development capabilities to accelerate the translation of academic discoveries into novel therapeutics Under the agreement, Charles River will make an equity investment in Autobahn Labs Justin Bryans, Chief Scientific Officer, Discovery at Charles River, named to Autobahn's Board of Directors Charles River Laboratories International, Inc. (NYSE:CRL) and Autobahn Labs, a Samsara BioCapital-backed virtual accelerator for academic biotech, today announced a collaborative relationship that establishes Charles River as the preferred research partner to support Autobahn's grow
Charles River Laboratories International, Inc. (NYSE:CRL) today announced the appointment of Reshema Kemps-Polanco, Executive Vice President and Chief Commercial Officer, Novartis US, to its Board of Directors. Ms. Kemps-Polanco has extensive pharmaceutical industry experience in leading commercial organizations that will provide a wealth of healthcare business leadership knowledge and sales and marketing expertise to Charles River's Board. As a member of the Board, Ms. Kemps-Polanco will serve on the Compensation and Strategic Planning and Capital Allocation Committees. "Reshema Kemp-Polanco's deep industry experience at two of the top-10, global pharmaceutical companies and demonstrated
Strategic partnership includes co-development of patient-derived xenograft (PDX) Digital Twins for in vivo oncology researchCharles River to make an equity investment in Aitia as part of the agreementWILMINGTON, Mass. and SOMERVILLE, Mass., Nov. 13, 2023 /PRNewswire/ -- Charles River Laboratories International, Inc. (NYSE:CRL) and Aitia, a leader in the application of Causal AI and Digital Twins, today announced a strategic agreement that gives Aitia access to Logica™, Charles River's Artificial Intelligence (AI) powered drug solution platform, for the optimized discovery and early development of multiple therapeutic programs for neurodegenerative disease and oncology.
Strategic partnership includes co-development of patient-derived xenograft (PDX) Digital Twins for in vivo oncology research Charles River to make an equity investment in Aitia as part of the agreement Charles River Laboratories International, Inc. (NYSE:CRL) and Aitia, a leader in the application of Causal AI and Digital Twins, today announced a strategic agreement that gives Aitia access to Logica™, Charles River's Artificial Intelligence (AI) powered drug solution platform, for the optimized discovery and early development of multiple therapeutic programs for neurodegenerative disease and oncology. This press release features multimedia. View the full release here: https://www.bu
Charles River Laboratories International, Inc. (NYSE:CRL) today announced the re-appointment of Craig B. Thompson, M.D., former President and Chief Executive Officer, Memorial Sloan-Kettering Cancer Center, to its Board of Directors. Dr. Thompson previously served as a member of Charles River's Board of Directors from 2013 through 2018. Dr. Thompson's extensive scientific expertise in the fields of immuno-oncology and translational and precision medicine, together with his healthcare business leadership experience, will provide a unique contribution of knowledge and guidance to Charles River's Board. As a member of the Board, he will serve on the Science and Technology and Strategic Plannin
SC 13G/A - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Subject)
SC 13G/A - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Subject)
SC 13G/A - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Subject)
SC 13G/A - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Subject)
SC 13G - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Subject)
SC 13G/A - CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (0001100682) (Subject)